Novel CCR5 antagonists for the treatment of HIV infection: a review of compounds patented in 2006 – 2008

Bibliography

• Available from: http://www.who.int/hiv/data/2008_global_summary_AIDS_ep.png
   Google Scholar
• Perks-Ngarm S, Pitisuttithum P, Nitayaphan S, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Melby T, Westby M. Inhibitors of viral entry. Handb Exp Pharmacol 2009;189:177-202
   Google Scholar
• Leonard JT, Roy K. The HIV entry inhibitors revisited. Curr Med Chem 2006;13(8):911-34
   PubMed Web of Science ®Google Scholar
• Pierson TC, Doms RW, Poehlmann S. Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol 2004;14(4):255-70
   PubMed Web of Science ®Google Scholar
• Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004;36(1):35-8
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico AL, Garzino-Demo A, Identification of RANTES, MIP-1.alpha., and MIP-1.beta. as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270(5243):1811-15
   PubMed Web of Science ®Google Scholar
• Deng H, Liu R, Ellmeier W, Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381(6584):661-6
   PubMed Web of Science ®Google Scholar
• Dean M, Carrington M, Winkler C, Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structure gene. Science 1996;273(5283):1856-62
   PubMed Web of Science ®Google Scholar
• Dorr P, Perros M. CCR5 inhibitors in HIV-1 therapy. Expert Opin Drug Discov 2008;3(11):1345-61
   PubMed Web of Science ®Google Scholar
• Repik A, Richards KH, Clapham PR. The promise of CCR5 antagonists as new therapies for HIV-1. Curr Opin Invest Drugs 2007;8(2):130-9
   PubMedGoogle Scholar
• Barber CG. CCR5 antagonists for the treatment of HIV. Curr Opin Invest Drugs 2004;5(8):851-61
   PubMedGoogle Scholar
• Baba M, Nishimura O, Kanzaki N, A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Nat Acad Sci USA 1999;96(10):5698-703
   PubMed Web of Science ®Google Scholar
• Hale JJ, Budhu RJ, Mills SG, 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg Med Chem Lett 2001;11(11):1437-40
   PubMed Web of Science ®Google Scholar
• Hale JJ, Budhu RJ, Holson, 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent Anti-HIV activity. Bioorg Med Chem Lett 2001;11(20):2741-5
   PubMed Web of Science ®Google Scholar
• Hale JJ, Budhu RJ, Mills SG, 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity. Bioorg Med Chem Lett 2002;12(20):2997-3000
   PubMed Web of Science ®Google Scholar
• Lynch CL, Hale JJ, Budhu RJ, 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. Bioorg Med Chem Lett 2002;12(20):3001-4
   PubMed Web of Science ®Google Scholar
• Lynch CL, Willoughby CA, Hale JJ, 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists: modifications of the arylpropylpiperidine side chains. Bioorg Med Chem Lett 2003;13(1):119-23
   PubMed Web of Science ®Google Scholar
• Willoughby CA, Rosauer KG, Hale JJ, 1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains. Bioorg Med Chem Lett 2003;13(3):427-31
   PubMed Web of Science ®Google Scholar
• Kim D, Wang L, Hale JJ, Design, antiviral and pharmacokinetic profiles of potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists for the treatment of HIV-1 infection. Abstracts of Papers, 226th ACS National Meeting, New York, NY, United States, September 7-11, 2003, MEDI-162
   Google Scholar
• Kim D, Wang L, Hale JJ, Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties. Bioorg Med Chem Lett 2005;15(8):2129-34
   PubMed Web of Science ®Google Scholar
• Cohen C, DeJesus E, Mills A, Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days monotherapy. Sydney, Australia: 4th IAS Conferences on AIDS Pathogenesis, Treatment and Prevention, July 22-25, 2007
   Google Scholar
• Available from: http://www.incyte.com/drugs_product_pipeline.html
   Google Scholar
• Ness TL, Kunkel SL, Hogaboam CM. CCR5 antagonists: the answer to inflammatory disease? Expert Opin Ther Pat 2006;16(8):1051-65
   PubMed Web of Science ®Google Scholar
• Kuritzkes D, Kar S, Kirkpatrick P. Maraviroc. Nat Rev Drug Disc 2008;7(1):15-6
   Web of Science ®Google Scholar
• Sayana S, Khanlou H. Maraviroc: a new CCR5 antagonist. Expert Rev Anti Infect Ther 2008;7(1):9-19
   Web of Science ®Google Scholar
• Dorr P, Westby M, McFadyen L, PF-232798, a second generation oral CCR5 antagonist. 15th Conference on Retroviruses and Opportunistic Infections, 3-6 February 2008, Boston, MA. Abstract 737
   Google Scholar
• Pfizer. 8-Azabicyclo[3.2.1]octane derivatives with an activity on chemokine CCR5 receptors and their preparation, pharmaceutical compositions and use for treatment of inflammatory diseases and infection caused by HIV and genetically related retroviruses. WO2006067584; 2006
   Google Scholar
• Pfizer. Preparation of 1,4′-bipiperidinyl carboxamide derivatives as chemokine CCR5 receptor antagonists. WO2006077499; 2006
   Google Scholar
• Tagat JR, McCombie SW, Nazareno D, Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)phenyl}ethyl-3(S)-methyl-1-piperazinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004;47:2405-8
   PubMed Web of Science ®Google Scholar
• Pfizer. Preparation of triazolylpiperidine derivatives for use as CCR5 receptor modulators for treating various diseases. WO2006136917; 2006
   Google Scholar
• Pfizer. Piperidine derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of chemokine CCR5 receptors. WO2007066201; 2007
   Google Scholar
• Barber CG, Fenwick DR, Pryde DC, Stephenson PT. Preparation of piperidine derivatives as modulators, especially antagonists, of chemokine CCR5 receptors. WO2007116313; 2007
   Google Scholar
• Strizki JM, Tremblay C, Xu S, Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005;49(12):4911-9
   PubMed Web of Science ®Google Scholar
• Schering Plough. Piperazine derivatives and their preparation, pharmaceutical compositions and use as CCR5 antagonists for treatment of human immunodeficiency virus or inflammatory diseases. US2006105964; 2006
   Google Scholar
• Schering Corp. Preparation of piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors. WO2006091692; 2006
   Google Scholar
• Schering Corp. Piperidinylpiperidine derivatives useful as inhibitors of chemokine receptors and their preparation and pharmaceutical compositions; 2006. CODEN: PIXXD2 WO 2006091534 A1 20060831 CAN 145:293046 AN 2006:885318 CAPLUS
   Google Scholar
• Schering Corp. CCR5 antagonists useful for treating HIV. US2007203149; 2007
   Google Scholar
• Schering Corp. Synthesis of CCR5 receptor antagonists. WO2006074270; 2006
   Google Scholar
• Schering Corp. Preparation of 4-substituted piperidinyl derivatives as intermediates for synthesizing CCR-5 receptor antagonists. WO2008079284; 2008
   Google Scholar
• Schering Corp. Preparation of pharmaceutical salts of piperazine compounds. WO2006074269; 2006
   Google Scholar
• Ono Pharmaceutical. Preparation of N-containing heterocyclic compounds as CCR5 antagonists. WO2006030925; 2006
   Google Scholar
• Ono Pharmaceutical. Preparation of nitrogenated heterocyclic derivatives as antagonists of chemokine receptor 5 (CCR5). WO2007105637; 2007
   Google Scholar
• AstraZeneca. Preparation of piperidine derivatives as CCR5 modulators. WO2006001751; 2006
   Google Scholar
• AstraZeneca. Preparation of piperidine and 8-azabicyclo[3.2.1]octane derivatives as modulators of chemokine receptor CCR5. WO2006001752; 2006
   Google Scholar
• AstraZeneca. Process for the preparation of N-(4-piperidinyl)-N-ethylphenylacetamides from N-Boc-4-oxopiperidine. WO2006064221; 2006
   Google Scholar
• AstraZeneca. Preparation of 4-[3-(1,1-difluoroethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-1-{(1R,3R)-3-(3,5-difluorophenyl)-1-methyl-3-[1-(methylsulfonyl)piperidin-4-yl]propyl}piperidine for the treatment of CCR5 disease. US2008139612; 2008
   Google Scholar
• Astrazeneca. Preparation of 4-{(1R,3R)-1-(3,5-difluorophenyl)-3-[4-(3-ethyl-5-isopropyl-4H-1,2,4-triazol-4-yl)piperidin-1-yl]butyl}-1-(methylsulfonyl)piperidine for use in the treatment of CCR5 mediated diseases. US2008139613; 2008
   Google Scholar
• Roche. Preparation of 1-oxa-3,9-diazaspiro[5.5]undecan-2-ones and 1-oxa-3,8-diazasprio[4.5]decan-2-ones as CCR5 receptor antagonists for treating inflammatory and infectious diseases. US2005176703; 2005
   Google Scholar
• Rotstein DM, Gabriel SD, Makra F, Spiropiperidine CCR5 antagonists. Bioorg Med Chem Lett 2009;19(18):5401
   PubMed Web of Science ®Google Scholar
• Roche. Heterocyclic derivatives as CCR5 receptor ligands and their preparation, pharmaceutical compositions and use in the treatment of viral infections. WO2008119663; 2008
   Google Scholar
• Roche. Preparation of heterocyclic antiviral compounds, particularly (3-hexahydropyrrolo[3,4-c]pyrrol-2-yl)-1-phenylpropylamine and [3-(hexahydropyrrolo[3,4-c]pyrrol-2-yl)propyl]phenylamine derivatives as antagonists of chemokine CCR5 receptor, useful for treating HIV and genetically related retroviral infections. WO2005121145; 2005
   Google Scholar
• Roche. Preparation of 3,7-diazabicyclo[3.3.0]octane CCR5 chemokine receptor antagonists useful as antiaids drugs. US2007191335; 2007
   Google Scholar
• Roche. Preparation of 3,7-diazabicyclo[3.3.0]octane compounds as antiviral agents. WO2007093515; 2007
   Google Scholar
• Roche. Pyrrolo[3,4-c]pyrrole derivatives as heterocyclic antiviral compounds and CCR5 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of HIV infection, AIDS and ARC. US2007191406; 2007
   Google Scholar
• Roche. Octahydropyrrolo[3,4-c]pyrrole derivatives as antiviral agents and their preparation, pharmaceutical compositions and use in the treatment of HIV infection. WO2008034731; 2008
   Google Scholar
• GSK. Preparation of pyrrolidine and azetidine compounds as CCR5 antagonists. WO2004055016; 2004
   Google Scholar
• ViroChem Pharma. Preparation of spirohydantoins for the modulation of chemokine receptor activity. WO2006000096; 2006
   Google Scholar
• ViroChem Pharma. Preparation of spirotropane compounds and methods for the modulation of chemokine receptor activity to block cellular entry of HIV. WO2006060918; 2006
   Google Scholar
• ViroChem Pharma. Preparation of spirotropane compounds and therapeutic use as modulators of chemokine receptor activity. WO2006060919; 2006
   Google Scholar
• ViroChem Pharma. Preparation of novel spiropiperidine compounds for the modulation of chemokine receptor activity. WO2007065256; 2007
   Google Scholar
• ViroChem Pharma. Spirotropane compounds, processes for preparing them, pharmaceutical compositions containing them, and their use as modulators of CCR5 chemokine receptors. WO2007143847; 2007
   Google Scholar
• AnorMed Inc. Preparation of piperidinyl substituted ureas and amides as chemokine receptor binding compounds. WO2006138350; 2006
   Google Scholar
• AnorMed Inc. Substituted imidazolidinones and related compounds as chemokine receptor binding compounds and their preparation, pharmaceutical compositions and use in the treatment of infection of target cells by human immunodeficiency virus. WO2007022371; 2007
   Google Scholar
• Genzyme Corp. Preparation of piperidine derivatives as modulators of chemokine receptor in particular CCR5 receptor. WO2008070758; 2008
   Google Scholar
• Kemia. Preparation of aryl bicyclo and spiro compounds as therapeutic modulators of CCR-5 activity. WO2006130426; 2006
   Google Scholar
• Ernst J, Dahl R, Lum C, Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. Bioorg Med Chem Lett 2008;18(4):1498-501
   PubMed Web of Science ®Google Scholar
• Yang H, Lin X-F, Padilla F, Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undecan-2-one CCR5 antagonist. Bioorg Med Chem Lett 2009;19(1):209-13
   PubMed Web of Science ®Google Scholar
• Auspex Pharmaceuticals. 8-Azabicyclo[3.2.1]octane-base compounds, preparation and utility of CCR5 inhibitors and use in the treatment of infections. US2008146605; 2008
   Google Scholar
• Concert Pharmaceuticals. Preparation of deuterated triazolyl tropane derivatives as CCR5 receptor inhibitors. WO2008063600; 2008
   Google Scholar
• Benson SW. The C–D bond strength is considered to be 0.9 kcal greater than that of C–H: foundations of chemical kinetics. Mc-Graw-Hill Book Co., Inc.: New York; 1960. p. 676
   Google Scholar
• Long Y, Song Y, Jiang X. Shanghai Institute of Materia Medica. Preparation of 4-(piperazin-1-yl)-piperidine derivatives as chemokine receptor inhibitors for treatment of AIDS. CN1789263; 2006
   Google Scholar
• Shanghai Target Drug Corp. Preparation of piperidine derivatives as CCR5 antagonists for treatment of AIDS. CN1939916; 2007
   Google Scholar
• Ma D, Yu S, Li B, Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally bioavailable anti-HIV agent. ChemMedChem 2007;2(2):187-93
   PubMed Web of Science ®Google Scholar
• Price DA, Armour D, De Groot M, Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg Med Chem Lett 2006;16(17):4633-37
   PubMed Web of Science ®Google Scholar
• Pearlstein R, Vaz R, Rampe D. Understanding the structure–activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem 2003;46(11):2017-22
   PubMed Web of Science ®Google Scholar
• Kim JK, Louie CY, Glaser C, Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile Virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008;197:262-5
   PubMed Web of Science ®Google Scholar
• Dummond JB, Paterson KB, Pecha AL, Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acuir Immune Defic Syndr 2009;51(5):546-53
   PubMed Web of Science ®Google Scholar
• Ness TL, Kunkel SL, Hogaboam CM. CCR5 antagonists: the answer to inflammatory disease? Expert Opin Ther Pat 2006;16(8):1051-65
   PubMed Web of Science ®Google Scholar